No Prescription |
 |
 | ||
|
Danocrine (Danazol) |
|
| ||
No Prescription » Pain Medicine » Danocrine (Danazol) Danocrine (Danazol) is a synthetic steroid used to treat endometriosis and fibrocystic breast disease. It may also be used to treat excessive menstrual bleeding. Buy Danocrine (Danazol) and other Pain Medicine products online at Medstore. Buy Online at Medstore - Click Here!
About Danocrine (Danazol): Product Type: Pain Medicine Brand name: Danocrine Generic name: Danazol Classification: Synthetic androgen (gonadotropin inhibitor) Action/Kinetics: Inhibits the release of gonadotropins (FSH and LH) by the anterior pituitary; thus inhibits synthesis of sex steroids and competitively inhibits binding of steroids to their cytoplasmic receptors in target tissues. In women this action arrests ovarian function induces amenorrhea and causes atrophy of normal and ectopic endometrial tissue. Has weak androgenic effects. Onset fibrocystic disease: 4 weeks. Time to peak effect amenorrhea and anovulation: 6-8 weeks; fibrocystic disease: 2-3 months to eliminate breast pain and tenderness and 4-6 months for elimination of nodules. t 1/2: 4.5 hr. Duration: Ovulation and cyclic bleeding usually resume 60-90 days after cessation of therapy. Uses: Endometriosis amenable to hormonal management in clients who cannot tolerate or who have not responded to other drug therapy. Fibrocystic breast disease. Hereditary angioedema in males and females. Investigational: Gynecomastia menorrhagia precocious puberty idiopathic immune thrombocytopenia lupus-associated thrombocytopenia and autoimmune hemolytic anemia. Contraindications: Undiagnosed genital bleeding; markedly impaired hepatic renal and cardiac function; pregnancy and lactation. Special Concerns: Use with caution in children treated for hereditary angioedema due to the possibility of virilization in females and precocious sexual development in males. Use with caution in conditions aggravated by fluid retention (e.g. epilepsy migraine cardiac or renal dysfunction). Geriatric clients may have an increased risk of prostatic hypertrophy or prostatic carcinoma. Side Effects: Androgenic: Acne decrease in breast size oily hair and skin weight gain deepening of voice and hair growth clitoral hypertrophy testicular atrophy. Estrogen deficiency: Flushing sweating vaginitis nervousness changes in emotions. GI: N&V constipation gastroenteritis. Hepatic: Jaundice dysfunction. CNS: Fatigue tremor headache dizziness sleep problems paresthesia of extremities anxiety depression appetite changes. Musculoskeletal: Muscle cramps or spasms joint swelling or lock-up pain in back legs or neck. Miscellaneous: Allergic reactions (skin rashes and rarely nasal congestion) hematuria increased BP chills pelvic pain carpal tunnel syndrome hair loss change in libido. Drug Interactions: Insulin / Insulin requirements Warfarin / PT in warfarin-stabilized clients How Supplied: Capsule: 50 mg 100 mg 200 mg Generic Danocrine (Danazol) Danogen 100mg 100 pills 100mg 20 pills 200mg 40 pills 100mg 50 pills 50mg 150 pills 100mg 30 pills 200mg 50 pills 200mg 10 pills 50mg 30 pills 100mg 40 pills 50mg 100 pills 200mg 20 pills 50mg 40 pills 200mg 30 pills 50mg 50 pills Danazol Danocrine
View more Pain Medicine No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
